IRAK4 PROTAC Degrader Architecture for Selective Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IRAK4 degraders lack structural diversity, therapeutic differentiation, and good safety, limiting their clinical application for treating inflammatory diseases.
Innovation Solution
Development of a bifunctional compound, a tripartite PROTAC molecule, specifically designed to target IRAK4 for degradation by recruiting it to an E3 ubiquitin ligase, comprising a target structure, linker, and degron, with specific functional groups and linkages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PROTAC technology is used to degrade IRAK4, then therapeutic effectiveness for inflammatory diseases is improved, but structural diversity and therapeutic differentiation are insufficient
Solution Approach 1:
The PROTAC molecule is segmented into three functional modules: an IRAK4-binding ligand (TBM), a linker, and an E3 ligase-recruiting ligand (degron). This segmentation allows independent optimization of each module to achieve both high degradation effectiveness and structural diversity. The patent describes this tripartite structure in detail, showing how each component can be varied to create multiple therapeutic candidates with different properties.
Solution Approach 2:
The patent employs universal E3 ligase recruiting ligands (such as VHL and CRBN binders) that can be combined with different IRAK4-binding ligands through appropriate linkers. This multi-functionality approach allows a single E3 ligase module to serve multiple PROTAC candidates, enabling systematic exploration of structural diversity while maintaining reliable IRAK4 degradation through the conserved E3 ligase mechanism.
2Reliability
If PROTAC molecules are designed to target IRAK4, then degradation capability is achieved, but safety and tolerability need improvement
Solution Approach 1:
The patent applies local quality by using highly selective IRAK4-binding ligands that specifically recognize and bind to IRAK4 with high affinity, while the E3 ligase recruiting ligand is designed to engage only with specific E3 ligases (VHL or CRBN). This localized specificity at each binding interface ensures that degradation is targeted precisely to IRAK4, minimizing off-target effects and improving safety. The patent emphasizes the importance of selectivity in each module to achieve safe therapeutic outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional compound effectively degrades IRAK4, offering potential therapeutic benefits for inflammatory diseases with improved safety and clinical diversity.
Implementation Method 1
The PROTAC molecule recruits the target protein (TBM) to the E3 ligase by binding to the target protein, enabling the E3 ligase to ubiquitinate the target protein (the E2 enzyme linked to the E3 ligase brings the TBM into sufficiently close proximity for polyubiquitination). The ubiquitinated target protein can be degraded via the proteasomal pathway.
Data Source
Figure 1~2
AI summary
The present invention relates to an IRAK4 degrader and a use thereof, and specifically relates to a bifunctional compound as represented by formula (I), an isomer thereof, a deuterated product thereof, or a pharmaceutically acceptable salt thereof, and a use of the compound in treatment for IRAK4-mediated related diseases.